Piramal Pharma Ltd: Q4FY26 results
Piramal Pharma Ltd reported revenue of Rs 2,752 cr and net profit of Rs -9 cr for Q4FY26.
Filed 28 Apr 2026, 21:09 IST · after market close · Piramal Pharma Ltd (PPLPHARMA)
Price around the results
What was reported
Piramal Pharma Ltd reported revenue of Rs 2,752 cr and net profit of Rs -9 cr for Q4FY26. Figures are consolidated.
How it compares
Revenue changed -0.08% from a year earlier. Against the previous quarter revenue changed +28.60%.
How the stock reacted
The stock closed -2.63% on the session after the results.
Q4FY26 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q4FY26 | Q3FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹2,752 cr | ₹2,140 cr | +28.60% | -0.08% |
| Other income | ₹-116 cr | ₹12 cr | — | — |
| Expenses | ₹2,291 cr | ₹1,944 cr | +17.85% | +4.48% |
| Operating profit | ₹461 cr | ₹196 cr | +135.28% | -17.91% |
| Operating margin (%) | 16.74% | 9.15% | — | — |
| Interest | ₹83 cr | ₹89 cr | -7.00% | -19.96% |
| Depreciation | ₹218 cr | ₹213 cr | +2.65% | -10.04% |
| Profit before tax | ₹43 cr | ₹-94 cr | — | -84.23% |
| Tax | ₹52 cr | ₹42 cr | +22.44% | -56.55% |
| Net profit | ₹-9 cr | ₹-136 cr | +93.52% | — |
| EPS (₹) | ₹-0.07 | ₹-1.03 | +93.20% | — |
Operating margin of 16.74% compares with a Healthcare sector median of 23.38% across 48 peers that have reported Q4FY26.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | -2.63% | -3.38% |
| Next session | -1.58% | — |
| 5 sessions | +11.71% | +10.33% |
| 15 sessions | +7.06% | — |
| 30 sessions | -0.38% | — |
Volume on the results session was 1.03× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Guidance & outlook
- Piramal expects all three businesses to grow in FY27, with accelerated growth in EBITDA and PAT.
- Piramal expects growth in inhalation anesthesia to accelerate in FY27 as India-facility supplies ramp up.
- Piramal expects overseas sites to enable a sharp profitability turnaround through onshoring trends and regulatory changes.
Expansion
- Piramal has US$90 million of capex underway to scale sterile injectable and payload-linker capacities at Lexington and Riverview.
New products
- Piramal launched 31 new products and SKUs in FY26, focusing on premiumization.
New initiatives
- Piramal will continue its cost optimization and operational excellence programmes in FY27.
- Piramal is improving e-commerce profitability through customer acquisition, premiumization and advertising optimization.
Competition
- Piramal maintained the number-one position in US Sevoflurane with a 47% value share.
Problems & risks
- Initial growth in ex-US inhalation anesthesia markets was muted because of intensified competition.
- Piramal continues to work with its supplier to resolve injectable pain management supply constraints.